|
Exclusivity Code |
Definition |
|---|---|
| D | NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES) |
|
|
|
| D-1 | ONCE A DAY APPLICATION |
|
|
|
| D-2 | ONCE DAILY DOSING |
|
|
|
| D-3 | SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE |
|
|
|
| D-4 | SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE |
|
|
|
| D-5 | TEN DAYS/ELEVEN DAYS DOSING SCHEDULE |
|
|
|
| D-6 | SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE |
|
|
|
| D-7 | BID DOSING |
|
|
|
| D-8 | INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING |
|
|
|
| D-9 | NARCOTIC OVERDOSE IN ADULTS |
|
|
|
| D-10 | NARCOTIC OVERDOSE IN CHILDREN |
|
|
|
| D-11 | POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN |
|
|
|
| D-12 | BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER |
|
|
|
| D-13 | INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION |
|
|
|
| D-14 | BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
|
|
|
| D-15 | SINGLE DAILY DOSE OF 25MG/37.5MG |
|
|
|
| D-16 | CONTINUOUS INTRAVENOUS INFUSION |
|
|
|
| D-17 | 400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS |
|
|
|
| D-18 | LOWER RECOMMENDED STARTING DOSE GUIDELINES |
|
|
|
| D-19 | BOLUS DOSING GUIDELINES |
|
|
|
| D-20 | SINGLE 32MG DOSE |
|
|
|
| D-21 | ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL |
|
|
|
| D-22 | REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE |
|
|
|
| D-23 | INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN |
|
|
|
| D-24 | FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS |
|
|
|
| D-25 | ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN |
|
|
|
| D-26 | ONCE WEEKLY APPLICATION |
|
|
|
| D-27 | BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY |
|
|
|
| D-28 | USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300 |
|
|
|
| D-29 | INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS |
|
|
|
| D-30 | 5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS |
|
|
|
| D-31 | CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID) |
|
|
|
| D-32 | REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS |
|
|
|
| D-33 | ONCE DAILY DOSING FOR PLAQUE PSORIASIS |
|
|
|
| D-34 | EVERY FOUR MONTHS DOSAGE REGIMEN |
|
|
|
| D-35 | FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS |
|
|
|
| D-36 | FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY |
|
|
|
| D-37 | DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID) |
|
|
|
| D-38 | CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION |
|
|
|
| D-39 | CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..." |
|
|
|
| D-40 | ONCE-A-DAY DOSING REGIMEN |
|
|
|
| D-41 | DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS |
|
|
|
| D-42 | TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE |
|
|
|
| D-43 | INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD |
|
|
|
| D-44 | IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED |
|
|
|
| D-45 | ONCE DAILY DOSING FOR MAINTENANCE ONLY |
|
|
|
| D-46 | NEW DOSING REGIMEN OF 80MG DAILY |
|
|
|
| D-47 | PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL |
|
|
|
| D-48 | ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL |
|
|
|
| D-49 | PEDIATRIC DOSING GUIDELINES |
|
|
|
| D-50 | INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS |
|
|
|
| D-51 | OPTIONAL STARTING DOSE OF 40MG/DAY |
|
|
|
| D-52 | ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY |
|
|
|
| D-53 | USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE |
|
|
|
| D-54 | USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS |
|
|
|
| D-55 | ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK) |
|
|
|
| D-56 | ADDITION OF POSTPRANDIAL DOSING |
|
|
|
| D-57 | 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER |
|
|
|
| D-58 | CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION |
|
|
|
| D-59 | REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY |
|
|
|
| D-60 | ADDITION OF A POST-OPERATIVE DOSING REGIMEN |
|
|
|
| D-61 | ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-62 | ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-63 | TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE |
|
|
|
| D-64 | INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML |
|
|
|
| D-65 | CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS |
|
|
|
| D-66 | DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI |
|
|
|
| D-67 | SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES |
|
|
|
| D-68 | CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS |
|
|
|
| D-69 | SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS |
|
|
|
| D-70 | 80MG ONCE DAILY DOSING REGIMEN |
|
|
|
| D-71 | EIGHT WEEK DOSING REGIMEN |
|
|
|
| D-72 | INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON |
|
|
|
| D-73 | ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-74 | ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-75 | INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE |
|
|
|
| D-76 | FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED |
|
|
|
| D-77 | ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%) |
|
|
|
| D-78 | USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS |
|
|
|
| D-79 | NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE |
|
|
|
| D-80 | CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING |
|
|
|
| D-81 | NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS |
|
|
|
| D-82 | USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-83 | 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP) |
|
|
|
| D-84 | ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS |
|
|
|
| D-85 | LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE |
|
|
|
| D-86 | FOR USE IN SELECT EXTERNAL INSULIN PUMPS |
|
|
|
| D-87 | ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
|
|
|
| D-88 | NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES |
|
|
|
| D-89 | USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS |
|
|
|
| D-90 | ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS |
|
|
|
| D-91 | ALTERNATE INTERMITTENT DOSING REGIMEN |
|
|
|
| D-92 | ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME |
|
|
|
| D-93 | ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS |
|
|
|
| D-94 | NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD) |
|
|
|
| D-95 | BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE |
|
|
|
| D-96 | ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS |
|
|
|
| D-97 | PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE |
|
|
|
| D-98 | DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE |
|
|
|
| D-99 | ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS |
|
|
|
| D-100 | 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS |
|
|
|
| D-101 | ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER |
|
|
|
| D-102 | NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER |
|
|
|
| D-103 | NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY. |
|
|
|
| D-104 | 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS |
|
|
|
| D-105 | USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| D-106 | FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA |
|
|
|
| D-107 | PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
|
|
|
| D-108 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS |
|
|
|
| D-109 | PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE |
|
|
|
| D-110 | TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17 |
|
|
|
| D-111 | PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION |
|
|
|
| D-112 | PROVIDES FOR PEDIATRIC PUMP USE |
|
|
|
| D-113 | ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN |
|
|
|
| D-114 | NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS |
|
|
|
| D-115 | STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED |
|
|
|
| I | NEW INDICATION (SEE INDIVIDUAL REFERENCES) |
|
|
|
| I-1 | DYSMENORRHEA |
|
|
|
| I-2 | CHOLANGIOPANCREATOGRAPHY |
|
|
|
| I-3 | INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY |
|
|
|
| I-4 | PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY) |
|
|
|
| I-5 | HYSTEROSALPINGOGRAPHY |
|
|
|
| I-6 | TREATMENT OF JUVENILE ARTHRITIS |
|
|
|
| I-7 | BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN |
|
|
|
| I-8 | ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY |
|
|
|
| I-9 | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING |
|
|
|
| I-10 | PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY |
|
|
|
| I-11 | RELIEF OF MILD TO MODERATE PAIN |
|
|
|
| I-12 | TREATMENT OF CUTANEOUS CANDIDIASIS |
|
|
|
| I-13 | URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI |
|
|
|
| I-14 | SEBORRHEIC DERMATITIS |
|
|
|
| I-15 | PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT |
|
|
|
| I-16 | STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM |
|
|
|
| I-17 | MANAGEMENT OF CONGESTIVE HEART FAILURE |
|
|
|
| I-18 | ENDOSCOPIC RETROGRADE PANCREATOGRAPHY |
|
|
|
| I-19 | HERNIOGRAPHY |
|
|
|
| I-20 | KNEE ARTHROGRAPHY |
|
|
|
| I-21 | HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR |
|
|
|
| I-22 | RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA |
|
|
|
| I-23 | SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
|
|
|
| I-24 | TREATMENT OF RHEUMATOID ARTHRITIS |
|
|
|
| I-25 | ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS |
|
|
|
| I-26 | TREATMENT OF LIVER FLUKES |
|
|
|
| I-27 | ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE |
|
|
|
| I-28 | SELECTIVE ADULT VISCERAL ARTERIOGRAPHY |
|
|
|
| I-29 | METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION |
|
|
|
| I-30 | TREATMENT OF TINEA PEDIS |
|
|
|
| I-31 | CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES |
|
|
|
| I-32 | PEDIATRIC MYELOGRAPHY |
|
|
|
| I-33 | ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN |
|
|
|
| I-34 | ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT |
|
|
|
| I-35 | PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING |
|
|
|
| I-36 | ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS |
|
|
|
| I-37 | RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS |
|
|
|
| I-38 | CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER) |
|
|
|
| I-39 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION |
|
|
|
| I-40 | PRIMARY NOCTURNAL ENURESIS |
|
|
|
| I-41 | MIGRAINE HEADACHE PROPHYLAXIS |
|
|
|
| I-42 | HERPES ZOSTER |
|
|
|
| I-43 | HERPES SIMPLEX ENCEPHALITIS |
|
|
|
| I-44 | MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY |
|
|
|
| I-45 | ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS |
|
|
|
| I-46 | USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING |
|
|
|
| I-47 | TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE |
|
|
|
| I-48 | PEDIATRIC ANGIOCARDIOGRAPHY |
|
|
|
| I-49 | TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI |
|
|
|
| I-50 | FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER |
|
|
|
| I-51 | TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS |
|
|
|
| I-52 | PEDIATRIC EXCRETORY UROGRAPHY |
|
|
|
| I-53 | TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA |
|
|
|
| I-54 | RENAL CONCENTRATION CAPACITY TEST |
|
|
|
| I-55 | HYPERTENSION |
|
|
|
| I-56 | EROSIVE GASTROESOPHAGEAL REFLUX DISEASE |
|
|
|
| I-57 | SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER |
|
|
|
| I-58 | INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS |
|
|
|
| I-59 | ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE |
|
|
|
| I-60 | SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE |
|
|
|
| I-61 | FEMALE ANDROGENETIC ALOPECIA |
|
|
|
| I-62 | PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| I-63 | ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION |
|
|
|
| I-64 | PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS |
|
|
|
| I-65 | PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS |
|
|
|
| I-66 | UNCOMPLICATED GONORRHEA |
|
|
|
| I-67 | TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER |
|
|
|
| I-68 | CENTRAL PRECOCIOUS PUBERTY |
|
|
|
| I-69 | SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY |
|
|
|
| I-70 | USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER |
|
|
|
| I-71 | VARICELLA INFECTIONS (CHICKENPOX) |
|
|
|
| I-72 | PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE |
|
|
|
| I-73 | INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES |
|
|
|
| I-74 | INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY |
|
|
|
| I-75 | TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS |
|
|
|
| I-76 | PREVENTION OF OSTEOPOROSIS |
|
|
|
| I-77 | DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM |
|
|
|
| I-78 | CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY |
|
|
|
| I-79 | MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM |
|
|
|
| I-80 | DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE |
|
|
|
| I-81 | PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS |
|
|
|
| I-82 | TREATMENT OF TRAVELERS' DIARRHEA |
|
|
|
| I-83 | ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN |
|
|
|
| I-84 | INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION |
|
|
|
| I-85 | TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS |
|
|
|
| I-86 | TREATMENT OF SECONDARY CARNITINE DEFICIENCY |
|
|
|
| I-87 | RENAL IMAGING AGENT FOR USE IN CHILDREN |
|
|
|
| I-88 | MANAGEMENT OF ENDOMETRIOSIS |
|
|
|
| I-89 | EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE |
|
|
|
| I-90 | INTENSIVE CARE UNIT SEDATION |
|
|
|
| I-91 | MONOTHERAPY USE FOR HYPERTENSION |
|
|
|
| I-92 | ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE |
|
|
|
| I-93 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS |
|
|
|
| I-94 | USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART] |
|
|
|
| I-95 | TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION |
|
|
|
| I-96 | TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA |
|
|
|
| I-97 | ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT |
|
|
|
| I-98 | TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY |
|
|
|
| I-99 | PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER |
|
|
|
| I-100 | TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY |
|
|
|
| I-101 | TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY |
|
|
|
| I-102 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER |
|
|
|
| I-103 | PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA |
|
|
|
| I-104 | TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY |
|
|
|
| I-105 | TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY |
|
|
|
| I-106 | TREATMENT OF ACROMEGALY |
|
|
|
| I-107 | VAGINAL CANDIDIASIS |
|
|
|
| I-108 | EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION |
|
|
|
| I-109 | TYPHOID FEVER |
|
|
|
| I-110 | PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY |
|
|
|
| I-111 | TREATMENT OF PAGET'S DISEASE OF BONE |
|
|
|
| I-112 | MANAGEMENT OF MODERATE TO SEVERE PAIN |
|
|
|
| I-113 | TREATMENT OF PROSTATITIS |
|
|
|
| I-114 | USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE |
|
|
|
| I-115 | USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK |
|
|
|
| I-116 | MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS |
|
|
|
| I-117 | TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE |
|
|
|
| I-118 | PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY |
|
|
|
| I-119 | TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY |
|
|
|
| I-120 | MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS |
|
|
|
| I-121 | EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS |
|
|
|
| I-122 | PSORIASIS OF THE SCALP |
|
|
|
| I-123 | RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER |
|
|
|
| I-124 | LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE |
|
|
|
| I-125 | EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES |
|
|
|
| I-126 | ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY |
|
|
|
| I-127 | TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS |
|
|
|
| I-128 | IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS... |
|
|
|
| I-129 | TREATMENT OF ALCOHOL DEPENDENCE |
|
|
|
| I-130 | MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS |
|
|
|
| I-131 | PERIPHERAL ARTERIOGRAPHY |
|
|
|
| I-132 | TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER |
|
|
|
| I-133 | MANAGEMENT OF CHRONIC STABLE ANGINA |
|
|
|
| I-134 | HEART FAILURE POST MYOCARDIAL INFARCTION |
|
|
|
| I-135 | BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA |
|
|
|
| I-136 | IDIOPATHIC CHRONIC URTICARIA |
|
|
|
| I-137 | PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES |
|
|
|
| I-138 | TREATMENT OF ACUTE RECURRENT GENITAL HERPES |
|
|
|
| I-139 | PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN |
|
|
|
| I-140 | PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE |
|
|
|
| I-141 | TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL |
|
|
|
| I-142 | LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION |
|
|
|
| I-143 | EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS |
|
|
|
| I-144 | ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS |
|
|
|
| I-145 | 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN |
|
|
|
| I-146 | CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS |
|
|
|
| I-147 | PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS |
|
|
|
| I-148 | TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR |
|
|
|
| I-149 | TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER |
|
|
|
| I-150 | TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER |
|
|
|
| I-151 | PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA |
|
|
|
| I-152 | SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS |
|
|
|
| I-153 | MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN] |
|
|
|
| I-154 | PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE |
|
|
|
| I-155 | TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT |
|
|
|
| I-156 | ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE |
|
|
|
| I-157 | TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES |
|
|
|
| I-158 | TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER |
|
|
|
| I-159 | FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES |
|
|
|
| I-160 | TREATMENT OF BACTERIAL CORNEAL ULCERS |
|
|
|
| I-161 | TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY |
|
|
|
| I-162 | FOR USE IN PATIENTS 6-11 YEARS OF AGE |
|
|
|
| I-163 | TREATMENT OF PHOTOPHOBIA |
|
|
|
| I-164 | CHRONIC BACTERIAL PROSTATITIS |
|
|
|
| I-165 | MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS |
|
|
|
| I-166 | TREATMENT OF BULIMIA |
|
|
|
| I-167 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS |
|
|
|
| I-168 | MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS) |
|
|
|
| I-169 | USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER |
|
|
|
| I-170 | PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS |
|
|
|
| I-171 | RELIEF OF SYMPTOMS OF THE COMMON COLD |
|
|
|
| I-172 | TREATMENT OF INITIAL EPISODE OF GENITAL HERPES |
|
|
|
| I-173 | PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY |
|
|
|
| I-174 | PELVIC INFLAMMATORY DISEASE |
|
|
|
| I-175 | TREATMENT OF TINEA CORPORIS AND TINEA CRURIS |
|
|
|
| I-176 | TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION |
|
|
|
| I-177 | TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS |
|
|
|
| I-178 | TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN |
|
|
|
| I-179 | NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE |
|
|
|
| I-180 | TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE) |
|
|
|
| I-181 | TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION |
|
|
|
| I-182 | TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME |
|
|
|
| I-183 | MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11 |
|
|
|
| I-184 | TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG) |
|
|
|
| I-185 | PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
|
|
|
| I-186 | TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE) |
|
|
|
| I-187 | PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
|
|
|
| I-188 | TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS |
|
|
|
| I-189 | TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS |
|
|
|
| I-190 | PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS |
|
|
|
| I-191 | ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING |
|
|
|
| I-192 | THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION |
|
|
|
| I-193 | TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY |
|
|
|
| I-194 | CONGESTIVE HEART FAILURE |
|
|
|
| I-195 | FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER |
|
|
|
| I-196 | ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
|
|
|
| I-197 | MAINTENANCE OF HEALING OF DUODENAL ULCER |
|
|
|
| I-198 | FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER |
|
|
|
| I-199 | MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES |
|
|
|
| I-200 | TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR |
|
|
|
| I-201 | EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS |
|
|
|
| I-202 | SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA |
|
|
|
| I-203 | MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS |
|
|
|
| I-204 | USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
|
|
|
| I-205 | INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS |
|
|
|
| I-206 | TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE |
|
|
|
| I-207 | FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS |
|
|
|
| I-208 | TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION |
|
|
|
| I-209 | PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT) |
|
|
|
| I-210 | TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS |
|
|
|
| I-211 | FOR USE IN PEDIATRIC POPULATION |
|
|
|
| I-212 | TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME |
|
|
|
| I-213 | TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY |
|
|
|
| I-214 | TREATMENT OF OSTEOPOROSIS |
|
|
|
| I-215 | PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS |
|
|
|
| I-216 | FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
|
|
|
| I-217 | PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY |
|
|
|
| I-218 | USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV) |
|
|
|
| I-219 | USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET |
|
|
|
| I-220 | TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH |
|
|
|
| I-221 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY |
|
|
|
| I-222 | PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN |
|
|
|
| I-223 | USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS |
|
|
|
| I-224 | FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
|
|
|
| I-225 | USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS |
|
|
|
| I-226 | FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN |
|
|
|
| I-227 | SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD) |
|
|
|
| I-228 | PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL |
|
|
|
| I-229 | PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE |
|
|
|
| I-230 | IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION |
|
|
|
| I-231 | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY |
|
|
|
| I-232 | TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY |
|
|
|
| I-233 | PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY |
|
|
|
| I-234 | FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER |
|
|
|
| I-235 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER |
|
|
|
| I-236 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
|
|
|
| I-237 | MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
|
|
|
| I-238 | ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS |
|
|
|
| I-239 | TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
|
|
|
| I-240 | MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS |
|
|
|
| I-241 | USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER |
|
|
|
| I-242 | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS |
|
|
|
| I-243 | USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS |
|
|
|
| I-244 | REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER |
|
|
|
| I-245 | TREATMENT OF ACUTE SINUSITIS |
|
|
|
| I-246 | TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS |
|
|
|
| I-247 | USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG |
|
|
|
| I-248 | INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM |
|
|
|
| I-249 | TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY |
|
|
|
| I-250 | PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C |
|
|
|
| I-251 | TREATMENT OF GENERALIZED ANXIETY DISORDER |
|
|
|
| I-252 | NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN |
|
|
|
| I-253 | COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN |
|
|
|
| I-254 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS) |
|
|
|
| I-255 | PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP) |
|
|
|
| I-256 | USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY |
|
|
|
| I-257 | TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION |
|
|
|
| I-258 | FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE |
|
|
|
| I-259 | PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY |
|
|
|
| I-260 | EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER) |
|
|
|
| I-261 | TREATMENT OF SOCIAL ANXIETY DISORDER |
|
|
|
| I-262 | TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12 |
|
|
|
| I-263 | TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY |
|
|
|
| I-264 | PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION |
|
|
|
| I-265 | TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER |
|
|
|
| I-266 | USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES |
|
|
|
| I-267 | USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES |
|
|
|
| I-268 | PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE |
|
|
|
| I-269 | PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN |
|
|
|
| I-270 | ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY |
|
|
|
| I-271 | TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
|
|
|
| I-272 | TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY |
|
|
|
| I-273 | ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB) |
|
|
|
| I-274 | |